

# Monoclonal antibodies against CGRP pathway in patients with migraine. Experience in a Headache Clinic

Nagel Vanesa, Cavanagh Sol, Grandinetti Mariela, Calvo Daniela, Gutierrez Teresa, Larripa Natalia, Bravo Yasmin, Tajan Emilia, Bonamico Lucas, Goicochea Teresa



Headache Clinic. Department of Neurology. Fleni. Argentina

## Introduction:

Calcitonin gene-related peptide (CGRP) plays an important role in the pathophysiology of migraine through nociceptive mechanisms in the trigeminovascular system. Several studies demonstrate the safety and effectiveness of monoclonal antibodies (mAbs) against CGRP or its receptor as preventive treatment for episodic migraine (EM) and chronic migraine (CM).

## Objectives:


To evaluate the experience of treatment with mAbs against CGRP pathway in patients with EM and CM evaluated at a headache service in Argentina.

## Materials and Methods:


Retrospective, descriptive study. We reviewed electronic medical records of patients evaluated in our headache service with EM or CM who received Erenumab (70 or 140 mg) or Fremanezumab (225 mg) in monthly subcutaneous injections as preventive treatment of migraine between 07/2019 and 03/2022. The following information was obtained: age, sex, headache days/month (HDM), medication overuse headache, migraine preventive medication (in the previous month and at 3, 6, 12 months after starting treatment), type and dose of mAbs, adverse effects (AE) and response at 3, 6 and 12 months after starting treatment (reduction less than 30%, between 30 to 50%, greater than 50% or no reduction in HDM).

## Results:


- 69 patients were included (86% women, 14% men) with a mean age of 51 years old
- 83% used Erenumab and 17% Fremanezumab




Graphic 1




Graphic 2



Graphic 3



Graphic 4



Graphic 5

- 14 discontinued: 9 because no response, 4 because costs, while 1 because fertility treatment.
- 12 presented adverse effects, constipation was the most frequent. All received Erenumab and no one had to stop treatment.
- 32 patients (50%) had MOH before treatment: 17 completed 12-months follow-up, 16 of them without MOH.

## Conclusion:

In real world Erenumab and Fremanezumab are effective as preventive treatment for patients with EM and CM, even in those who failed with other treatments, including botulinum toxin.

A reduction in the overuse of analgesic medication was registered.

Good adherence and tolerance were observed, without discontinuation of treatment due to AE.

It is necessary to consider mAbs treatment in patients with EM or CM who have not responded to previous treatments.

## References:

1. The prevalence of migraine in Argentina: A reappraisal. Marco Lisicki, María L. Figuerola, Lucas Bonamico, Daniel Lew, María T. Goicochea. Headache Group of the Argentinian Neurological Society. Cephalalgia 2021 Jun;41(7):821-826. 2. Efficacy and safety of calcitonin gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis Hong Deng, Gai-gai Li, Hao Nie, Yang-yang Feng, Guang-yu Guo, Wen-liang Guo and Zhou-ping Tang. BMC 2020 3. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study. Peter J. Goadsby, MD, PhD, Stephen D. Silberstein, MD, Paul P. Yeung, MD, MPH, Joshua M. Cohen, MD, MPH, Xiaoping Ning, MD, MS, Ronghua Yang, PhD, and David W. Dodick, MD. Neurology | Volume 95, Number 18 | November 3, 2020 4. Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months Edoardo Caronna, Victor José Gallardo, Alicia Alpuente, Marta Torres-Ferrus and Patricia Pozo-Rosich. Caronna et al. The Journal of Headache and Pain (2021) 22:120 <https://doi.org/10.1186/s10194-021-01328-1>